FDA Forces Recall of Tainted Kratom in Rare Use of Agency Power
(Bloomberg) -- The U.S. Food and Drug Administration is forcing a Las Vegas company to recall its kratom plant-based products after several tested positive for salmonella, in a rare instance of the agency using its power to pull a food product off the market.
The unusual use of recall authority the FDA gained under a 2011 food-safety law is part of a wider government offensive against kratom, which the FDA says affects the brain similarly to the opioid morphine and could lead to addiction. The crackdown has created a fierce backlash from proponents who tout the herb as an alternative to opioids.
The FDA asked Triangle Pharmanaturals to pull its kratom from the market on Friday but the company refused, according to an agency statement.
The regulator warned consumers earlier this year not to use kratom, which has been linked to a salmonella outbreak that has infected at least 87 people from 35 states, causing 27 hospitalizations and leading some sellers to issue voluntarily recalls. Salmonella symptoms include diarrhea, fever and abdominal pain.
This is the first time the FDA has forced a recall after giving a company the opportunity to do so voluntarily.
“Our first approach is to encourage voluntary compliance, but when we have a company like this one, which refuses to cooperate, is violating the law, and is endangering consumers; we will pursue all avenues of enforcement under our authority,” said FDA Commissioner Scott Gottlieb in the statement.
Other kratom sellers have previously pulled their products off of shelves after running afoul of FDA rules by selling the herb as a dietary supplement.
“We continue to have serious concerns about the safety of any kratom-containing product and we are pursuing these concerns separately,” Gottlieb said.
Oregon public-health officials found the salmonella-tainted kratom from Triangle Pharmanaturals as part of product testing at the store Torched Illusions in Tigard, Oregon. Other kratom products sold at Torched Illusions have been linked to the salmonella outbreak under investigation by the FDA and the Centers for Disease Control and Prevention, but the Triangle Pharmanaturals strain differs from the ones linked to the outbreak, according to the FDA.
To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net.
To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett
©2018 Bloomberg L.P.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.